Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Gross Margin (2020 - 2026)

Insight Molecular Diagnostics' Gross Margin history spans 6 years, with the latest figure at 43.55% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 351.0% to 43.55% in Q4 2025 year-over-year; TTM through Dec 2025 was 56.97%, a 1763.0% increase, with the full-year FY2025 number at 56.67%, up 1733.0% from a year prior.
  • Gross Margin hit 43.55% in Q4 2025 for Insight Molecular Diagnostics, down from 53.46% in the prior quarter.
  • Over the last five years, Gross Margin for IMDX hit a ceiling of 72.47% in Q4 2021 and a floor of 401.49% in Q3 2022.
  • Historically, Gross Margin has averaged 5.26% across 5 years, with a median of 41.76% in 2024.
  • Biggest five-year swings in Gross Margin: surged 98828bps in 2021 and later plummeted -31348bps in 2022.
  • Tracing IMDX's Gross Margin over 5 years: stood at 72.47% in 2021, then tumbled by -114bps to 9.85% in 2022, then crashed by -278bps to 37.26% in 2023, then soared by 207bps to 40.04% in 2024, then increased by 9bps to 43.55% in 2025.
  • Business Quant data shows Gross Margin for IMDX at 43.55% in Q4 2025, 53.46% in Q3 2025, and 67.57% in Q2 2025.